Skip to main content Back to Top
Advertisement

11/21/2022

Ropivacaine Injection

Products Affected - Description

    • Naropin injection, Fresenius Kabi, 2 mg/mL, 10 mL Steripak plastic ampule, 5 count, NDC 63323-0285-10
    • Naropin injection, Fresenius Kabi, 2 mg/mL, 100 mL premixed bag, 1 count, NDC 63323-0285-61
    • Naropin injection, Fresenius Kabi, 2 mg/mL, 20 mL Steripak plastic ampule, 5 count, NDC 63323-0285-20
    • Naropin injection, Fresenius Kabi, 2 mg/mL, 200 mL premixed bag, 1 count, NDC 63323-0285-63
    • Naropin injection, Fresenius Kabi, 5 mg/mL, 100 mL infusion bottle, 1 count, NDC 63323-0286-00
    • Naropin injection, Fresenius Kabi, 5 mg/mL, 20 mL Steripak plastic ampule, 5 count, NDC 63323-0286-20
    • Naropin injection, Fresenius Kabi, 5 mg/mL, 30 mL Steripak plastic ampule, 5 count, NDC 63323-0286-31
    • Naropin injection, Fresenius Kabi, 7.5 mg/mL, 20 mL vial, 25 count, NDC 63323-0287-21
    • Ropivacaine injection, Akorn, 5 mg/mL, 30 mL vial, 1 count, NDC 17478-0081-30
    • Ropivacaine injection, Baxter, 10 mg/mL, 20 mL vial, 10 count, NDC 43066-0027-10
    • Ropivacaine injection, Baxter, 2 mg/mL, 20 mL vial, 10 count, NDC 43066-0015-10
    • Ropivacaine injection, Baxter, 5 mg/mL, 20 mL vial, 10 count, NDC 43066-0019-10
    • Ropivacaine injection, Baxter, 5 mg/mL, 30 mL vial, 10 count, NDC 43066-0023-10
    • Ropivacaine injection, Hikma, 2 mg/mL, 20 mL vial, 10 count, NDC 00143-9263-10
    • Ropivacaine injection, Pfizer, 10 mg/mL, 10 mL vial, 10 count, NDC 00409-9303-10 - discontinued
    • Ropivacaine injection, Pfizer, 10 mg/mL, 20 mL vial, 10 count, NDC 00409-9303-20 - discontinued
    • Ropivacaine injection, Pfizer, 2 mg/mL, 10 mL vial, 10 count, NDC 00409-9300-10 - discontinued
    • Ropivacaine injection, Pfizer, 2 mg/mL, 20 mL vial, 10 count, NDC 00409-9300-20 - discontinued
    • Ropivacaine injection, Pfizer, 5 mg/mL, 30 mL vial, 10 count, NDC 00409-9301-30 - discontinued
    • Ropivacaine injection, Pfizer, 7.5 mg/mL, 20 mL vial, 10 count, NDC 00409-9302-20 - discontinued

Reason for the Shortage

    • Akorn had ropivacaine on shortage due to increased demand.
    • Baxter has ropivacaine on shortage due to increase demand.
    • Eugia has ropivacaine on back order due to shortage of active ingredient.
    • Fresenius Kabi has Naropin on shortage due to increased demand and manufacturing delays.
    • Pfizer discontinued ropivacaine in August 2022.
    • Sagent did not provide a reason for the shortage.
    • Somerset Therapeutics has ropivacaine 5 mg/mL 30 mL vials available.

Available Products

    • Naropin injection, Fresenius Kabi, 10 mg/mL, 10 mL Steripak plastic ampule, 5 count, NDC 63323-0288-10
    • Naropin injection, Fresenius Kabi, 10 mg/mL, 10 mL vial, 25 count, NDC 63323-0288-11
    • Naropin injection, Fresenius Kabi, 10 mg/mL, 20 mL Steripak plastic ampule, 5 count, NDC 63323-0288-20
    • Naropin injection, Fresenius Kabi, 10 mg/mL, 20 mL vial, 25 count, NDC 63323-0288-21
    • Naropin injection, Fresenius Kabi, 2 mg/mL, 10 mL vial, 25 count, NDC 63323-0285-13
    • Naropin injection, Fresenius Kabi, 2 mg/mL, 100 mL infusion bottle, 1 count, NDC 63323-0285-65
    • Naropin injection, Fresenius Kabi, 2 mg/mL, 20 mL vial, 25 count, NDC 63323-0285-23
    • Naropin injection, Fresenius Kabi, 2 mg/mL, 200 mL infusion bottle, 1 count, NDC 63323-0285-64
    • Naropin injection, Fresenius Kabi, 5 mg/mL, 20 mL vial, 25 count, NDC 63323-0286-23
    • Naropin injection, Fresenius Kabi, 5 mg/mL, 200 mL infusion bottle, 1 count, NDC 63323-0286-63
    • Naropin injection, Fresenius Kabi, 5 mg/mL, 30 mL vial, 25 count, NDC 63323-0286-35
    • Naropin injection, Fresenius Kabi, 7.5 mg/mL, 20 mL Steripak plastic ampule, 5 count, NDC 63323-0287-20
    • Ropivacaine injection, Eugia US, 10 mg/mL, 10 mL vial, 25 count, NDC 55150-0200-10
    • Ropivacaine injection, Eugia US, 10 mg/mL, 20 mL vial, 25 count, NDC 55150-0201-20
    • Ropivacaine injection, Eugia US, 2 mg/mL, 100 mL infusion bottle, 25 count, NDC 55150-0196-99
    • Ropivacaine injection, Eugia US, 2 mg/mL, 20 mL vial, 25 count, NDC 55150-0195-20
    • Ropivacaine injection, Eugia US, 5 mg/mL, 20 mL vial, 25 count, NDC 55150-0197-20
    • Ropivacaine injection, Eugia US, 5 mg/mL, 30 mL vial, 25 count, NDC 55150-0198-30
    • Ropivacaine injection, Eugia US, 7.5 mg/mL, 20 mL vial, 25 count, NDC 55150-0199-20
    • Ropivacaine injection, Sagent, 2 mg/mL, 100 mL premixed bag, 10 count, NDC 25021-0671-82
    • Ropivacaine injection, Sagent, 2 mg/mL, 200 mL premixed bag, 10 count, NDC 25021-0671-87
    • Ropivacaine injection, Sagent, 5 mg/mL, 100 mL premixed bag, 10 count, NDC 25021-0652-82
    • Ropivacaine injection, Sagent, 5 mg/mL, 200 mL premixed bag, 10 count, NDC 25021-0652-87
    • Ropivacaine injection, Somerset Therapeutics LLC, 2 mg/mL, 10 mL vial, 10 count, NDC 70069-0062-10
    • Ropivacaine injection, Somerset Therapeutics LLC, 2 mg/mL, 10 mL vial, 25 count, NDC 70069-0062-25
    • Ropivacaine injection, Somerset Therapeutics LLC, 5 mg/mL, 30 mL vial, 1 count, NDC 70069-0064-01
    • Ropivacaine injection, Somerset Therapeutics LLC, 5 mg/mL, 30 mL vial, 10 count, NDC 70069-0064-10
    • Ropivacaine injection, Somerset Therapeutics LLC, 5 mg/mL, 30 mL vial, 25 count, NDC 70069-0064-25

Estimated Resupply Dates

    • Baxter has ropivacaine 2 mg/mL 20 mL vials, 5 mg/mL 20 mL and 30 mL vials, and 10 mg/mL 20 mL vials available limited supply.
    • Fresenius Kabi has Naropin 2 mg/mL 10 mL and 20 mL Steripak ampules on back order and the company cannot estimate a release date. The 2 mg/mL 100 mL and 200 mL premixed bags are on back order and the company cannot estimate a release date. The 5 mg/mL 20 mL and 30 mL Steripak ampules are on back order and the company cannot estimate a release date. The 7.5 mg/mL 20 mL vials are on back order and the company estimates a release date of mid-January 2023. The 10 mg/mL 20 mL Steripak ampules are on back order and the company cannot estimate a release date.
    • Hikma has ropivacaine 2 mg/mL 20 mL vials on back order and the company cannot estimate a release date.

Updated

Updated November 21, 2022 by Michelle Wheeler, PharmD, Drug Information Specialist. Created January 27, 2018 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2022, Drug Information Service, University of Utah, Salt Lake City, UT.

ADVERTISEMENT

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.